每周多西他赛联合雄激素全阻断与图像引导调强放疗治疗局限性高危前列腺腺癌的Ⅰ期试验长期结局
这项Ⅰ期试验纳入19例高危局限性前列腺癌患者,在图像引导调强放疗(77.4 Gy/43次)及新辅助和同期联合雄激素阻断基础上,同步给予每周多西他赛10~30 mg/m²剂量递增。中位随访10.5年时,5年和10年总生存率分别为89.5%和68.4%,中位无转移生存期和无进展生存期分别为11.3年和9.0年,>2级毒性轻微;作者认为该方案值得进一步研究。
要点
- 同步每周多西他赛联合高剂量调强放疗和联合雄激素阻断的方案,>2级毒性轻微。
- 中位随访10.5年,5年和10年总生存率分别为89.5%和68.4%。
- 中位无转移生存期11.3年,中位无进展生存期9.0年。
核心结论
- 在19例高危局限性前列腺癌患者中,该方案取得10年总生存率68%、10年无转移生存率58%,>2级毒性轻微。
- 作者认为,这些有限的数据提示,在高剂量调强放疗基础上加用同步每周多西他赛治疗高危前列腺癌值得进一步研究。
研究设计与样本
- Ⅰ期试验,纳入19例高危、非转移性局限性前列腺腺癌患者。
- 治疗方案为图像引导调强放疗77.4 Gy/43次,同步每周多西他赛按10~30 mg/m²剂量递增,并给予新辅助及同期联合雄激素阻断(促性腺激素释放激素激动剂联合抗雄激素)。
- 放疗后促性腺激素释放激素激动剂继续使用24个月,采用Kaplan-Meier法估计生存概率。
主要发现
- 中位随访10.5年,5年总生存率为89.5%,10年总生存率为68.4%。
- 中位无转移生存期为11.3年,中位无进展生存期为9.0年。
- 10年无转移生存率为58%,>2级毒性轻微。
关键数值与推荐
- 同步每周多西他赛剂量范围为10~30 mg/m²,按剂量递增方案给药。
- 图像引导调强放疗剂量为77.4 Gy/43次。
- 放疗后促性腺激素释放激素激动剂继续使用24个月。
- >2级毒性轻微。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者称这些数据有限(limited data),并认为需要进一步研究(warrants further investigation)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to describe the long-term outcomes seen with the addition of concurrent weekly docetaxel to high-dose intensity modulated radiation (IMRT) to the prostate and androgen deprivation therapy in patients with high-risk nonmetastatic adenocarcinoma of the prostate. METHODS AND MATERIALS: Nineteen patients with high-risk, localized prostate cancer were treated in a phase I trial with concurrent docetaxel at doses of 10 to 30 mg/m2, in a dose-escalated scheme, in addition to IMRT (77.4 Gy/43 fx) and neoadjuvant and concurrent combined androgen blockade (gonadotropin-releasing hormone agonist and antiandrogen). A gonadotropin-releasing hormone agonist was continued for an additional 24 months post radiation. Kaplan-Meier analysis was used to estimate the survival probabilities. RESULTS: At a median follow-up of 10.5 years, 5-year and 10-year overall survival were found to be 89.5% and 68.4%, respectively. The median metastasis-free survival and progression-free survival were determined to be 11.3 years and 9.0 years, respectively. CONCLUSIONS: This regimen produced a 10-year overall survival of 68% with a 10-year metastasis-free survival of 58%. Grade >2 toxicity was minimal. These limited data suggest that the addition of concurrent weekly docetaxel to high-dose IMRT for high-risk prostate cancer warrants further investigation.
引用
- McVorran S, Keane T, Marshall DT, et al. Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma. Adv Radiat Oncol. 2022. PMID: 36420198. doi:10.1016/j.adro.2022.100935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。